Characterization of the α1-adrenoceptor subtype activating extracellular signal-regulated kinase in submandibular gland acinar cells

Michael R. Bruchas, Myron L. Toews, Charles Bockman, Peter W. Abel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

α1-Adrenoceptors and extracellular signal-regulated kinases 1 and 2 (ERK1/2) regulate salivary secretion. However, whether α1-adrenoceptors couple to ERK1/2 activation and the specific α1-adrenoceptor subtypes involved in salivary glands is unknown. Western blotting of ERK1/2 phosphorylation showed phenylephrine activated ERK1/2 by 2-3-fold in submandibular gland slices and 3-4-fold in submandibular acinar (SMG-C10) cells with an EC50 of 2.7 ± 2 μM. ERK1/2 activation was blocked by either prazosin or HEAT, indicating α1-adrenoceptors stimulate ERK1/2 in native glands and SMG-C10 cells. Inhibition of [125I]HEAT binding by 5-methylurapidil (selective for α1A over α1B/α1D), but not BMY 7378 (selective for α1D over α1A/α1B), was biphasic and best-fit by a two-site binding model with KiH and KiL values for 5-methylurapidil of 0.64 ± 0.3 and 91 ± 7 nM, respectively, in SMG-C10 membranes. From these binding data, we obtained subtype-selective concentrations of 5-methylurapidil to determine the α1-adrenoceptor subtype/s activating ERK1/2 in SMG-C10 cells. 5-methylurapidil (20 nM) did not affect phenylephrine- or A-61603- (α1A-selective agonist) induced ERK1/2 activation; whereas, 30 μM chloroethylclonidine (α1B-selective antagonist) inhibited ERK1/2 activation by phenylephrine, indicating α1B-adrenoceptors, but not α1A-adrenoceptors, activate ERK1/2 in submandibular cells. We also examined α1-adrenoceptor location and dependence on cholesterol-rich microdomains for activating ERK1/2. Sucrose density gradient centrifugation showed 71 ± 3% of α1-adrenoceptor binding sites were in plasma membranes. Cholesterol-disrupting agents filipin and methyl-β-cyclodextrin inhibited phenylephrine-stimulated ERK1/2. These results show only α1B-adrenoceptors activate ERK1/2 and suggest subtype-specific ERK1/2 signaling by α1B-adrenoceptors may be determined by localization to cholesterol-rich microdomains in submandibular cells.

Original languageEnglish
Pages (from-to)349-358
Number of pages10
JournalEuropean Journal of Pharmacology
Volume578
Issue number2-3
DOIs
StatePublished - Jan 14 2008

Fingerprint

Mitogen-Activated Protein Kinase 3
Acinar Cells
Submandibular Gland
Mitogen-Activated Protein Kinase 1
Extracellular Signal-Regulated MAP Kinases
Adrenergic Receptors
Phenylephrine
Cholesterol
A 61603
Binding Sites
Filipin
Density Gradient Centrifugation
Prazosin
Cyclodextrins
Salivary Glands
Sucrose

All Science Journal Classification (ASJC) codes

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Characterization of the α1-adrenoceptor subtype activating extracellular signal-regulated kinase in submandibular gland acinar cells. / Bruchas, Michael R.; Toews, Myron L.; Bockman, Charles; Abel, Peter W.

In: European Journal of Pharmacology, Vol. 578, No. 2-3, 14.01.2008, p. 349-358.

Research output: Contribution to journalArticle

@article{53abbfd7712e4ebdad61106ed8dc9fb3,
title = "Characterization of the α1-adrenoceptor subtype activating extracellular signal-regulated kinase in submandibular gland acinar cells",
abstract = "α1-Adrenoceptors and extracellular signal-regulated kinases 1 and 2 (ERK1/2) regulate salivary secretion. However, whether α1-adrenoceptors couple to ERK1/2 activation and the specific α1-adrenoceptor subtypes involved in salivary glands is unknown. Western blotting of ERK1/2 phosphorylation showed phenylephrine activated ERK1/2 by 2-3-fold in submandibular gland slices and 3-4-fold in submandibular acinar (SMG-C10) cells with an EC50 of 2.7 ± 2 μM. ERK1/2 activation was blocked by either prazosin or HEAT, indicating α1-adrenoceptors stimulate ERK1/2 in native glands and SMG-C10 cells. Inhibition of [125I]HEAT binding by 5-methylurapidil (selective for α1A over α1B/α1D), but not BMY 7378 (selective for α1D over α1A/α1B), was biphasic and best-fit by a two-site binding model with KiH and KiL values for 5-methylurapidil of 0.64 ± 0.3 and 91 ± 7 nM, respectively, in SMG-C10 membranes. From these binding data, we obtained subtype-selective concentrations of 5-methylurapidil to determine the α1-adrenoceptor subtype/s activating ERK1/2 in SMG-C10 cells. 5-methylurapidil (20 nM) did not affect phenylephrine- or A-61603- (α1A-selective agonist) induced ERK1/2 activation; whereas, 30 μM chloroethylclonidine (α1B-selective antagonist) inhibited ERK1/2 activation by phenylephrine, indicating α1B-adrenoceptors, but not α1A-adrenoceptors, activate ERK1/2 in submandibular cells. We also examined α1-adrenoceptor location and dependence on cholesterol-rich microdomains for activating ERK1/2. Sucrose density gradient centrifugation showed 71 ± 3{\%} of α1-adrenoceptor binding sites were in plasma membranes. Cholesterol-disrupting agents filipin and methyl-β-cyclodextrin inhibited phenylephrine-stimulated ERK1/2. These results show only α1B-adrenoceptors activate ERK1/2 and suggest subtype-specific ERK1/2 signaling by α1B-adrenoceptors may be determined by localization to cholesterol-rich microdomains in submandibular cells.",
author = "Bruchas, {Michael R.} and Toews, {Myron L.} and Charles Bockman and Abel, {Peter W.}",
year = "2008",
month = "1",
day = "14",
doi = "10.1016/j.ejphar.2007.09.029",
language = "English",
volume = "578",
pages = "349--358",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Characterization of the α1-adrenoceptor subtype activating extracellular signal-regulated kinase in submandibular gland acinar cells

AU - Bruchas, Michael R.

AU - Toews, Myron L.

AU - Bockman, Charles

AU - Abel, Peter W.

PY - 2008/1/14

Y1 - 2008/1/14

N2 - α1-Adrenoceptors and extracellular signal-regulated kinases 1 and 2 (ERK1/2) regulate salivary secretion. However, whether α1-adrenoceptors couple to ERK1/2 activation and the specific α1-adrenoceptor subtypes involved in salivary glands is unknown. Western blotting of ERK1/2 phosphorylation showed phenylephrine activated ERK1/2 by 2-3-fold in submandibular gland slices and 3-4-fold in submandibular acinar (SMG-C10) cells with an EC50 of 2.7 ± 2 μM. ERK1/2 activation was blocked by either prazosin or HEAT, indicating α1-adrenoceptors stimulate ERK1/2 in native glands and SMG-C10 cells. Inhibition of [125I]HEAT binding by 5-methylurapidil (selective for α1A over α1B/α1D), but not BMY 7378 (selective for α1D over α1A/α1B), was biphasic and best-fit by a two-site binding model with KiH and KiL values for 5-methylurapidil of 0.64 ± 0.3 and 91 ± 7 nM, respectively, in SMG-C10 membranes. From these binding data, we obtained subtype-selective concentrations of 5-methylurapidil to determine the α1-adrenoceptor subtype/s activating ERK1/2 in SMG-C10 cells. 5-methylurapidil (20 nM) did not affect phenylephrine- or A-61603- (α1A-selective agonist) induced ERK1/2 activation; whereas, 30 μM chloroethylclonidine (α1B-selective antagonist) inhibited ERK1/2 activation by phenylephrine, indicating α1B-adrenoceptors, but not α1A-adrenoceptors, activate ERK1/2 in submandibular cells. We also examined α1-adrenoceptor location and dependence on cholesterol-rich microdomains for activating ERK1/2. Sucrose density gradient centrifugation showed 71 ± 3% of α1-adrenoceptor binding sites were in plasma membranes. Cholesterol-disrupting agents filipin and methyl-β-cyclodextrin inhibited phenylephrine-stimulated ERK1/2. These results show only α1B-adrenoceptors activate ERK1/2 and suggest subtype-specific ERK1/2 signaling by α1B-adrenoceptors may be determined by localization to cholesterol-rich microdomains in submandibular cells.

AB - α1-Adrenoceptors and extracellular signal-regulated kinases 1 and 2 (ERK1/2) regulate salivary secretion. However, whether α1-adrenoceptors couple to ERK1/2 activation and the specific α1-adrenoceptor subtypes involved in salivary glands is unknown. Western blotting of ERK1/2 phosphorylation showed phenylephrine activated ERK1/2 by 2-3-fold in submandibular gland slices and 3-4-fold in submandibular acinar (SMG-C10) cells with an EC50 of 2.7 ± 2 μM. ERK1/2 activation was blocked by either prazosin or HEAT, indicating α1-adrenoceptors stimulate ERK1/2 in native glands and SMG-C10 cells. Inhibition of [125I]HEAT binding by 5-methylurapidil (selective for α1A over α1B/α1D), but not BMY 7378 (selective for α1D over α1A/α1B), was biphasic and best-fit by a two-site binding model with KiH and KiL values for 5-methylurapidil of 0.64 ± 0.3 and 91 ± 7 nM, respectively, in SMG-C10 membranes. From these binding data, we obtained subtype-selective concentrations of 5-methylurapidil to determine the α1-adrenoceptor subtype/s activating ERK1/2 in SMG-C10 cells. 5-methylurapidil (20 nM) did not affect phenylephrine- or A-61603- (α1A-selective agonist) induced ERK1/2 activation; whereas, 30 μM chloroethylclonidine (α1B-selective antagonist) inhibited ERK1/2 activation by phenylephrine, indicating α1B-adrenoceptors, but not α1A-adrenoceptors, activate ERK1/2 in submandibular cells. We also examined α1-adrenoceptor location and dependence on cholesterol-rich microdomains for activating ERK1/2. Sucrose density gradient centrifugation showed 71 ± 3% of α1-adrenoceptor binding sites were in plasma membranes. Cholesterol-disrupting agents filipin and methyl-β-cyclodextrin inhibited phenylephrine-stimulated ERK1/2. These results show only α1B-adrenoceptors activate ERK1/2 and suggest subtype-specific ERK1/2 signaling by α1B-adrenoceptors may be determined by localization to cholesterol-rich microdomains in submandibular cells.

UR - http://www.scopus.com/inward/record.url?scp=37349019686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349019686&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2007.09.029

DO - 10.1016/j.ejphar.2007.09.029

M3 - Article

VL - 578

SP - 349

EP - 358

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -